Faron Pharmaceuticals - Innovatiivisia lääketieteen ratkaisuja (Osa 2)

Tuossa todetaan että LAG-3:sta voisi tutkia enemmän:
“By contrast, LAG3 was the most consistently expressed checkpoint receptor in nonresponder patients, persisting across timepoints and T cell subsets, potentially implicating a dysfunctional T-cell population. Functional studies will be needed to provide further insight into this initial observation. Indeed, further exploration of the role of LAG3 in AML is warranted, given also the availability of targeted inhibitors”

1 tykkäys